HER Family mRNA Expression in Early Breast Cancer
Author Information
Author(s): Koutras A K, Kalogeras K T, Dimopoulos M-A, Wirtz R M, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos H P, Fountzilas G
Primary Institution: Hellenic Cooperative Oncology Group
Hypothesis
The study aims to evaluate the prognostic ability of HER family mRNA expression in early breast cancer and its predictive value for adjuvant treatment with paclitaxel.
Conclusion
The study found that EGFR and HER2 mRNA overexpression are associated with worse clinical outcomes, while HER3 and HER4 mRNA overexpression indicate better prognosis in high-risk early breast cancer.
Supporting Evidence
- EGFR and HER2 mRNA overexpression were associated with reduced overall survival.
- HER3 and HER4 mRNA levels had a favorable prognostic value.
- HER2 mRNA expression did not predict clinical benefit from paclitaxel.
Takeaway
This study looked at how certain genes related to breast cancer can help doctors understand how well patients might do and whether a specific treatment will help them.
Methodology
RNA was extracted from formalin-fixed paraffin-embedded tumor samples and analyzed using kinetic reverse transcription-polymerase chain reaction (kRT–PCR).
Potential Biases
Potential biases may arise from the retrospective nature of the study and the selection of patients from a single clinical trial.
Limitations
The study was retrospective and relied on archived tissue samples, which may affect RNA quality.
Participant Demographics
Patients were high-risk early breast cancer patients enrolled in the HE10/97 trial, with a median age of 51 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 90–96%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website